In Vitro and in Vivo Anti-Tumor Effect of Oridonin on Ovarian Cancer

Objective:To investigate in Vitro and in Vivo effects and the mechanism of oridonin on the growth of ovarian cancer . Methods:After human ovarian cancer cell line HO-8910PM was treated with different concentrations of oridonin, the cellular proliferation was detected by MTT assay. The flow cytometry was used to determine the apoptosis in ovarian cancer cells. Western blot was used to detect expressions of nuclear factor (NF)-κB and x-linked?inhibitor of apoptosis protein?(XIAP) in ovarian cancer cells. Furthermore, HO-8910PM cells were injected subcutaneously into nude mice to establish xenograft model. The tumor weight and inhibition rate were evaluated respectively after treatment with oridonin in nude mice. The positive expressions of Ki-67, NF-κB and XIAP in tumor tissues were detected by immunohistochemistry method. Results: The proliferation of ovarian cancer cells was inhibited significantly by oridonin. The cell viability values were (80.14±9.84)%, (71.68±6.51)% and (64.58±5.24)% respectively after treatment with the concentrations of oridonin 10, 20 and 40 μmol/L for 24 h, which were significantly lower than those (96.12±4.23)% in control group (P 0.05). Treatment with oridonin (40 μmol·L-1) for 24 h induced an early apoptosis with (15.9±3.4)% in HO-8910PM cells, which was significantly higher than that of control (1.7±0.3)%. Treatment with oridonin (10, 20 and 40 μmol·L-1) for 24 h in HO-8910PM cells induced the expression of NF-κB protein. The lower concentration of oridonin (10 μmol·L-1) had no inhibitory effect on the expression of XIAP in HO-8910PM cells. Meanwhile, the higher concentration of oridonin (20 and 40 μmol·L-1) significantly inhibited the expression of XIAP. Furthermore, the subcutaneous?tumor growth was significantly inhibited by oridonin in nude mice. The positive expressions of Ki-67, NF-κB and XIAP were significantly decreased in experimental group than those of control group (P 0.01). Conclusion: Oridonin exerts in vitro and in vivo anti-tumor activity in ovarian cancer , which may be related to the down-regulated levels of NF-κB and XIAP.